Axonics Modulation Technologies ( (AXNX) ) has released its Q3 earnings. Here is a breakdown of the information Axonics Modulation Technologies presented to its investors.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Axonics, Inc. is a medical technology company that develops and commercializes innovative products aimed at treating bladder and bowel dysfunction, primarily operating in the healthcare sector with a focus on minimally invasive solutions.
In its latest earnings report for the third quarter of 2024, Axonics reported a robust revenue growth of 25% year-over-year, driven by increased utilization of its sacral neuromodulation and Bulkamid products. Despite this growth, the company faced a slight net loss primarily due to one-time legal and acquisition-related costs.
The financial highlights include a net revenue of $116.2 million, with sacral neuromodulation and Bulkamid revenues both experiencing a 25% increase compared to the previous year. The gross margin improved to 77.2% from 74.2%, while the adjusted EBITDA rose significantly to $23.6 million from $14.0 million in the prior year period. However, the company reported a loss from operations of $6.3 million, influenced by $8 million in one-time expenses.
Looking ahead, Axonics remains committed to expanding its market presence and delivering life-changing therapies for incontinence. The management anticipates a positive trajectory as the company progresses towards its strategic goals and continues to innovate in its field.
